FiercePharmaAsia—Sandoz bets, Lupin sells in Japan; Dr. Reddy’s Zantac loss; Aslan’s varlitinib flop

15th November 2019 Uncategorised 0

Novartis’ Sandoz doubled down on Japan with a €400 million Aspen deal, as Lupin retreated from the country. Dr. Reddy’s detailed its loss from the U.S. recall of generic Zantac. Aslan’s lead drug, pan-HER inhibitor varlitinib, failed yet another critical trial. And more.

More: FiercePharmaAsia—Sandoz bets, Lupin sells in Japan; Dr. Reddy’s Zantac loss; Aslan’s varlitinib flop
Source: fierce